GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback